文献速递角膜与眼表疾病

磷酸地塞米松离子导入治疗非感染性非坏死性前巩膜炎的剂量探索临床试验

Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial.
PubMed 文献 · Br J Ophthalmol · 2018-04-17

这项首次人体随机双盲剂量递增试验评估磷酸地塞米松离子导入治疗巩膜炎的安全性和耐受性,18例样本量下治疗耐受良好且安全;最低剂量组(0.4 mA下1.2 mA/min)7眼中5眼在28天内达到主要疗效终点,提示可能有疗效。

要点

  • 首次人体随机双盲剂量递增试验评估磷酸地塞米松离子导入治疗巩膜炎。
  • 在18例样本量限制下,治疗耐受良好且安全。
  • 最低剂量组(0.4 mA下1.2 mA/min)7眼中5眼在28天内达到主要疗效终点。

核心结论

  • 磷酸地塞米松离子导入在18例样本量限制下耐受良好且安全。
  • 最低剂量组(0.4 mA下1.2 mA/min)7眼中5眼在28天内达到主要疗效终点,提示可能有疗效。
  • 作者认为离子导入皮质类固醇是巩膜炎有前景的潜在治疗方法,此1期试验显示良好的安全性和初步疗效结果。

研究设计与样本

  • 首次人体随机双盲剂量递增试验,评估磷酸地塞米松离子导入治疗巩膜炎,样本量18例。
  • 试验注册号NCT01059955。

主要发现

  • 治疗耐受良好且安全(在18例样本量限制下)。
  • 最低剂量组(0.4 mA下1.2 mA/min)7眼中5眼在28天内达到主要疗效终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量为18例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Currently available treatment options for non-infectious scleritis, including non-steroidal anti-inflammatory drugs, systemic corticosteroids and immunosuppressive therapies, have both efficacy and side effect limitations. Iontophoretic delivery of corticosteroids has been demonstrated to be effective for anterior uveitis and represents a potential new approach to scleritis therapy. We hypothesised that iontophoretic delivery would provide effective and precise medication delivery to the sclera, while limiting systemic exposure and side effects. This first-in-human randomised, double-masked, dose-escalating study of iontophoretic administration of dexamethasone phosphate for scleritis suggests the treatment to be well tolerated and safe (within the limitations of the 18 patients sample size). There was a suggestion of efficacy in the lowest (1.2 mA/min at 0.4 mA) dose group (corresponding to the superficial location of scleritis compared with anterior uveitis), with 5/7 eyes meeting the primary efficacy outcome within 28 days. Our results suggest iontophoretic delivery of corticosteroids is a promising potential treatment for scleritis, with favourable safety and preliminary efficacy results in this phase 1 trial. TRIAL REGISTRATION NUMBER: NCT01059955.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. O'Neil EC, Huang J, Suhler EB, et al. Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial. Br J Ophthalmol. 2018. PMID: 29666122. doi:10.1136/bjophthalmol-2017-311610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。